Seaport Therapeutics SPTX
NASDAQ SPTX
$19.12 -0.86 (-4.30%)
At close: Nov 16, 2026 · 4:00 PM EST

Seaport Therapeutics (SPTX) Gains (Losses) on Sale of Assets & Investments (2025 - 2026)

Updated

Seaport Therapeutics' Gains (Losses) on Sale of Assets & Investments was -$1.22 million in Q3 2026, compared with $99,000 a year earlier.

Analysis

Seaport Therapeutics (SPTX) Gains (Losses) on Sale of Assets & Investments (2025 - 2026) Analysis & Trends

On a trailing twelve-month basis, Seaport Therapeutics' Gains (Losses) on Sale of Assets & Investments was -$1.96 million through Sep 30, 2026; for FY2025, it was $310,000.

  • Per Business Quant data, SPTX's Gains (Losses) on Sale of Assets & Investments in the three quarters before Q3 2026 was -$557,000 (Q2 2026), -$252,000 (Q1 2026) and $78,000 (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn -
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn -
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn -
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn -
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn -
10 Seaport Therapeutics 1.03 Bn 63.31 Mn - -1.22 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -1.22 Mn
Jun 30, 2026 -557,000.00
Mar 31, 2026 -252,000.00
Dec 31, 2025 78,000.00
Sep 30, 2025 99,000.00
Jun 30, 2025 -59,000.00
Mar 31, 2025 192,000.00
API Access

Seaport Therapeutics Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=SPTX&period=max&api_key=YOUR_API_KEY